Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

INTRODUCTION: Deucravacitinib, a novel, oral, selective inhibitor of tyrosine kinase 2 (TYK2) signaling, acts via an allosteric mechanism by binding to the enzyme’s regulatory domain instead of the catalytic domain. This unique binding provides high functional selectivity for TYK2 versus the closely...

Descripción completa

Detalles Bibliográficos
Autores principales: Chimalakonda, Anjaneya, Burke, James, Cheng, Lihong, Catlett, Ian, Tagen, Michael, Zhao, Qihong, Patel, Aditya, Shen, Jun, Girgis, Ihab G., Banerjee, Subhashis, Throup, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484413/
https://www.ncbi.nlm.nih.gov/pubmed/34471993
http://dx.doi.org/10.1007/s13555-021-00596-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484413/
https://www.ncbi.nlm.nih.gov/pubmed/34471993
http://dx.doi.org/10.1007/s13555-021-00596-8

Ejemplares similares